The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Managing TP53-mutated MDS: current strategies and remaining therapeutic challenges
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, shares insights into managing patients with TP53-mutated myelodysplastic syndromes (MDS) and remaining therapeutic challenges. Dr Cluzeau notes that the current standard of care includes azacitidine and consideration of stem cell transplantation; however, poor patient outcomes persist, necessitating further clinical research. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
